Effect of the Endocannabinoid System on Migraine-Associated Pain via MAGL Inhibition
ABSTRACT Migraines are disabling neurological disorders, remaining a major unmet need with limited treatment options for some patients. The endocannabinoid system, which regulates pain through molecules such as 2-arachidonoylglycerol (2-AG), is a promising therapeutic target in aiding migraine-related pain. In a study by Mangutov et al. (2025), a novel and selected AMGL inhibitor (ABD-1970) was tested in both acute and chronic nitroglycerin (NTG)-triggered migraine models in male and female...
